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Abstract
Background: Limited data are available regarding the effects of combined administration of Cumin cyminum L. and lime on weight
loss and metabolic profiles among subjects with overweight subjects.
Objectives: The current study aimed to assess the effects of combined administration of Cumin cyminum L. and lime on weight loss
and metabolic profiles among subjects with overweight.
Patients and Methods: This randomized double-blind placebo-controlled clinical trial was conducted on 72 subjects with over-
weight, aged 18 - 50 years old. Participants were randomly divided into three groups: Group A received high-dose Cumin cyminum
L. and lime capsules (75 mg each, n = 24), group B low-dose Cumin cyminum L. and lime capsules (25 mg each, n = 24) and group C
placebos (n = 24) twice daily for eight weeks.
Results: After eight weeks of intervention, compared with low-doseC. cyminumL. plus lime and placebo, taking high-doseC. cyminum
L. plus lime resulted in significant weight loss (in the high-dose group: -2.1± 1.7 vs. in the low-dose group: -1.2± 1.5 and in the placebo
group: + 0.2± 1.3 kg, respectively; P < 0.001) and body mass index (-0.8± 0.6 vs. -0.5± 0.5 and +0.1± 0.5 kg/m2, respectively; P <
0.001). In addition, administration of high-doseC. cyminumL. plus lime compared with low-doseC. cyminumL. plus lime and placebo,
led to a significant reduction in fasting plasma glucose (FPG) (P < 0.001) and a significant rise in quantitative insulin sensitivity
check index (QUICKI) (+ 0.02± 0.02 vs. + 0.01± 0.02 and 0.01± 0.01, respectively; P = 0.01). Moreover, a significant decrease in
serum triglycerides (-14.1± 56.2 vs. +13.9± 36.8 and + 10.6± 25.1 mg/dL; respectively; P = 0.03), total-cholesterol (-18.4± 28.6 vs.
+8.6± 28.5 and -1.0± 24.8 mg/dL; respectively; P = 0.004) and low density lipoproteins- (LDL)-cholesterol levels (-11.8± 20.7 vs. +6.5
± 23.2 and -2.9± 20.4 mg/dL, respectively; P = 0.01) was observed following the consumption of high-dose C. cyminum L. plus lime
compared with low-dose C. cyminum L. plus lime and placebo.
Conclusions: Results of the current study indicated that taking high-dose C. cyminum L. plus lime for eight weeks among subjects
with overweight had beneficial effects on weight, BMI, FPG, QUICKI, triglycerides, total-cholesterol and LDL-cholesterol levels.
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1. Background
Obesity is an important worldwide public health prob-
lem resulted from the accumulation of excessive food en-
ergy intake into visceral fat (1). In addition, a link between
obesity and insulin resistance, increased lipid profiles and
oxidative stress is documented (2, 3). The prevalence of
obesity was reported 18.5% among Iranian adults (4). Pre-
vious studies reported that obesity is associated with a
number of co-morbidities including type 2 diabetes melli-
tus (T2DM), hypertension, cardiovascular diseases such as
heart failure and coronary heart disease (5), osteoarthritis
and liver steatosis (6).
Nowadays there is an increased demand for herbal
drugs to treat obesity instead of using synthetic ones,
which may have adverse effects and are more expensive.
Cuminum cyminum L. (cumin) from Apiaceae family is na-
tive to the Mediterranean region and is used in traditional
medicine including stomach disorders and diarrhea (7).
Lime is a tree from the citrus family (Rutaceae) with diverse
phytochemicals, including polyphenols and terpenes (8).
Authors previous study on subjects with overweight re-
vealed that taking 300 mg C. cyminum L. for eight weeks
results in significant decreases in weight, body mass in-
dex (BMI), insulin and homeostatic model assessment-Beta
cell function (HOMA-B), but did not influence lipid pro-
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files and biomarkers of oxidative stress (9). In addition,
another study by Asnaashari et al. (10) reported a signifi-
cant reduction in body weight following the consumption
of lime essential oil in mice after 45 days. D-limonene ad-
ministration also resulted in significant decreases in fast-
ing blood glucose (FPG), serum triglycerides, low density
lipoproteins- (LDL)-cholesterol levels and a significant in-
crease in high density lipoproteins- (HDL)-cholesterol in
obese mice (11).
Cuminum cyminum L. and lime intake may decrease
weight through inhibiting serotonin re-uptake in synap-
tic clefts (12), increased lipolysis and reduced appetite
(13). However, these findings might in turn suggest the
importance of cumin plus lime co-supplementation to
treat patients with obesity, the current study hypothesized
that cumin plus lime co-administration may contribute to
management of obesity and metabolic status. Authors are
aware of no reports evaluating the effects of C. cyminum
L. and lime co-administration on markers of insulin resis-
tance, lipid concentrations and biomarkers of oxidative
stress in subjects with overweight and obesity.
2. Objectives
The present study aimed to investigate the effects of
C. cyminum L. and lime co-administration on weight loss,
markers of insulin resistance, lipid concentrations and




The current randomized double-blind clinical trial in-
cluded 72 subjects aged 18 - 50 years with overweight or
obesity (BMI ≥ 25 kg/m2) from March 2015 to May 2015
in Kashan, Iran. The exclusion criteria were as follows:
individuals aged 18 - 50 years, BMI < 25 kg/m2, subjects
with hypertension, thyroid, diabetes or cardiovascular dis-
orders, pregnancy and lactation and the use of hormonal
or anti-obesity medications. Informed consent form was
taken from all subjects and the protocol was approved by
the ethics committee of Kashan University of Medical Sci-
ences (KUMS). The present study was carried out accord-
ing to the Helsinki declaration guidelines (9). The cur-
rent trial is recorded in the Iranian registry of clinical trial
(http://www.irct.ir: IRCT2015030812438N10) (9).
3.2. Study Design
After stratification for BMI (≥ 30 kg/m2) and age (≥ 40
y), subjects were randomly assigned to three groups receiv-
ing: 1) high-dose C. cyminum L. and lime capsules (75 mg
each, n = 24); 2) low-dose C. cyminum L. and lime capsules
(25 mg each, n = 24) and 3) placebos (n = 24) twice daily
for eight weeks. Individuals were requested to consume
lime before, and cumin after lunch and dinner. C. cyminum
L., lime and placebo capsules were produced by depart-
ment of the formulation of Barij medicinal plants research
center (Barij Essence Pharmaceutical, Kashan, Iran) (9).
To produce cumin and lime hard capsules, at first cumin
and lime essential oil was solved in poly ethylene glycol
4000 in 25°C, and then it was en-coated into a capsule
(9). Cumin cyminum L. and lime capsules were analyzed in
Barij Essence laboratory, Kashan, Iran by Gas chromatog-
raphy spectrometry method (9). The appearance of the
placebo capsules, such as color, shape, size, and packag-
ing were identical to cumin and lime (9). The random-
ized allocation sequence and participants’ assignment to
the groups were done by a trained nutritionist in the diet
therapy clinic. Compliance to the consumption of cumin,
lime and placebo capsules throughout the study was moni-
tored through asking participants to bring the medication
containers and receiving short message on cell phone by
the subjects (9). All participants completed three-day di-
etary records and three physical activity records during in-
tervention (9). Both dietary and physical activity records
were completed in weeks two, four and six of the interven-
tion. Physical activity was described as metabolic equiv-
alents (METs) in hour/day. To calculate the METs for each
subject, the times (hour/day) reported for each physical
activity was multiplied by its related METs coefficient by
standard tables (14). The current study used Nutritionist
4 software (First Data Bank, San Bruno, CA, USA) to deter-
mine the macro-and micro-nutrient intakes based on di-
etary records (9).
3.3. Endpoints and Sample Size Estimation
The primary endpoint of the current study was weight
and BMI. The secondary endpoints of the current study in-
cluded glucose homeostasis parameters, lipid profiles and
biomarkers of oxidative stress.
3.4. Assessment of Anthropometric and Clinical Measures
Weight was determined by a digital scale (Seca, Ham-
burg, Germany) to the nearest 0.1 kg (9). Height was mea-
sured by a non-stretched tape measure (Seca, Hamburg,
Germany) to the nearest 0.1 cm (9). Weight and height
were quantified according to standard protocols at the on-
set and end of the study in the diet therapy clinic by a
2 Iran Red Crescent Med J. 2016; 18(8):e34212.
Taghizadeh M et al.
trained nutritionist in an overnight fasting status with-
out shoes in a minimal clothing state (9). BMI was deter-
mined as weight in kilogram divided by height in meters
squared. Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were quantified via a sphygmomanometer
(ALPK2, Zhejiang, China). All anthropometric and clinical
measures were performed by a trained nutritionist. Fur-
thermore, the nutritionist was blinded to the randomiza-
tion assignments.
3.5. Biochemical Assessment
At the beginning of the study and after the eight-
week intervention, blood samples (10 mL) were took at
Kashan reference laboratory in an early morning after an
overnight fast (9). The current study used available en-
zymatic kits (Pars Azmun, Tehran, Iran) to quantify FPG,
serum triglycerides, total-cholesterol, LDL-cholesterol and
HDL-cholesterol (9). All inter- and intra-assay coefficients
of variations (CVs) for FPG and lipid concentrations were
less than 5%. Serum insulin was determined using the
enzyme-linked immunosorbent assay (ELISA) kit (DiaMe-
tra, Milano, Italy) with intra- and inter-assay CVs 2.3% and
5.2%, respectively. The homeostatic model of assessment
for insulin resistance (HOMA-IR), HOMA-B and the quanti-
tative insulin sensitivity check index (QUICKI) were deter-
mined based on the suggested formulas (15). Plasma to-
tal antioxidant capacity (TAC) and total glutathione (GSH)
were quantified using the ferric reducing ability of plasma
(FRAP) method developed by Benzie and Strain (16) and
that of Beutler et al. (17), respectively. All inter- and intra-
assay CVs for oxidative stress biomarkers were less than 5%.
Measurements of markers of insulin resistance, lipid con-
centrations and oxidative stress biomarkers were done in
a blinded fashion.
3.6. Statistical Methods
To evaluate the normal distribution of variables,
Kolmogrov-Smirnov test was applied. One-way analysis of
variance (ANOVA) was used to detect differences in gen-
eral characteristics and dietary intakes among the three
groups (9). Pearson Chi-square test was used to compare
the categorical variables. One-way repeated measures
analysis of variance was employed to compare changes
after eight weeks of intervention among the three groups.
In this analysis, the treatment (high-dose C. cyminum L.
plus lime vs. low-dose C. cyminum L. plus lime and placebo)
was regarded as between-subject factor and time with
two time-points (study baseline and after eight-week
intervention) was considered as within-subject factor.
To identify between-group differences for non-normally
distributed variables, Kruskal-Wallis test was used. Re-
sults of the normally distributed variables (all variables
except FPG) and non-normally distributed variables (FPG)
were presented as mean± standard deviations (SDs) and
median interquartile range (IQR), respectively. To control
the confounding markers (baseline values, age and BMI
at baseline), analysis of covariance (ANCOVA) was used.
The SPSS version 18 (SPSS Inc., Chicago, Illinois, USA) was
employed for statistical analyses. Statistical analyses were
blinded. The standard formula suggested for clinical trials
by considering type one error (α) of 0.05 and type two
error (β) of 0.20 (power = 80%) (9) was used to calculate
the sample size. Based on a previous randomized placebo-
controlled trial (9), 1.2 kg was used as SD and 1.1 kg as the
difference in mean (d) of weight loss as primary variable.
Therefore, the study needed20 subjects in each group.
Assuming dropouts of four subjects in each group, 24
subjects were selected for each group.
4. Results
At the screening visit, 250 subjects were screened in the
diet therapy clinic. One hundred-twenty-five subjects out
of 250 screened persons were excluded from the first visit.
Then, among the remaining 125 subjects assessed for eligi-
bility, 53 were excluded due to not living in Kashan (n = 23)
and unable to commit to the study (n = 30) (Figure 1). To-
tally, 72 subjects were randomized into three groups receiv-
ing: 1) high-dose C. cyminum L. and lime capsules (n=24);
2) low-dose C. cyminum L. and lime capsules (n = 24) and 3)
placebos (n=24); all subjects completed the trial. On aver-
age, the rate of compliance in the current study was high;
more than 90% of the capsules were taken throughout the
trial in the three groups.
Mean age and height of the study subjects were not sta-
tistically different among the three groups (Table 1). Base-
line weight and BMI, METs, SBP and DBP were not signifi-
cantly different among the three groups. After eight weeks
of intervention, compared with low-dose C. cyminum L.
plus lime and placebo, taking high-dose C. cyminum L. plus
lime resulted in a significant weight loss (changes from
baseline in the high-dose group: -2.1 ± 1.7 vs. in the low-
dose group: -1.2± 1.5 and in the placebo group: + 0.2± 1.3
kg, respectively; P < 0.001) and BMI (-0.8±0.6 vs. -0.5±0.5
and +0.1± 0.5 kg/m2, respectively; P < 0.001).
Comparison of the dietary intakes of the study subjects
throughout the study showed no significant changes in
macro-nutrient intakes including energy, carbohydrates,
proteins, fats, saturated fatty acids (SFA), polyunsaturated
fatty acid (PUFA), monounsaturated fatty acid (MUFA),
cholesterol and total dietary fiber (TDF) among the three
groups (Table 2).
After eight weeks of intervention, compared with low-
dose C. cyminum L. plus lime and placebo, high-dose C.
Iran Red Crescent Med J. 2016; 18(8):e34212. 3
































Assessed for Eligibility (n = 125)
Randomized (n = 72)
Allocated to Low-Dose
Cuminum Cyminum L. Plus
Lime (n = 24)
Lost to Follow-up (n = 0)Lost to Follow-up (n = 0) Lost to Follow-up (n = 0)




Cuminum Cyminum L. Plus
Lime (n = 24)
Excluded (n = 53)
Not living in Kashan (n = 23)
Unable to Commit to Study (n = 30)
Figure 1. A Summary of Patients’ Flow Diagram
cyminum L. plus lime administration led to significant re-
ductionin FPG (P < 0.001) and a significant elevation in
QUICKI (changes from baseline in the high-dose group:
+0.02± 0.02 vs. in the low-dose group: + 0.01± 0.02 and
in the placebo group: -0.01 ± 0.01, respectively; P = 0.01)
(Table 3). Moreover, a significant decrease in serum triglyc-
erides (-14.1± 56.2 vs. +13.9± 36.8 and +10.6± 25.1 mg/dL,
respectively; P = 0.03), total-cholesterol (-18.4±28.6 vs. +8.6
± 28.5 and -1.0± 24.8 mg/dL, respectively; P = 0.004) and
LDL-cholesterol levels (-11.8± 20.7 vs. +6.5± 23.2 and -2.9±
20.4 mg/dL, respectively; P = 0.01) was observed following
the consumption of high-doseC. cyminum L. plus lime com-
pared with low-dose C. cyminum L. plus lime and placebo.
High-dose C. cyminum L. plus lime intake had no signif-
icant effects on serum insulin, HOMA-IR, HOMA-B, HDL-
cholesterol and biomarkers of oxidative stress compared
with those of low-doseC. cyminum L. plus lime and placebo.
After adjusting the analysis for baseline values, age and
BMI at baseline, the above-mentioned findings remained
significant except for QUICKI (P = 0.06) and serum triglyc-
erides levels (P = 0.13) (Table 4).
5. Discussion
Results of the current study demonstrated that high-
dose C. cyminum L. plus lime administration for eight
weeks among subjects with overweight had beneficial
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Table 1. Demographic Data of Study Participantsa
Value Placebo Group, n = 24 Low-Dose Cuminum cyminum L. Plus
Lime Group, n = 24
High-Dose Cuminum cyminum L. Plus
Lime Group, n = 24
P Valueb
Gender 1.00c
Male 2 (8.3) 2 (8.3) 2 (8.3)
Female 22 (91.7) 22 (91.7) 22 (91.7)
Age, y 40.1±11.3 33.2± 11.8 34.5± 10.2 0.08
Height, cm 160.8± 7.0 164.2± 5.6 162.9± 6.1 0.18
Weight at study baseline, kg 83.4± 15.4 89.5± 16.1 82.3± 13.6 0.21
Weight at end-of-trial, kg 83.6± 15.8 88.3± 16.6 80.2± 13.5 0.20
Weight change, kg 0.2± 1.3 -1.2± 1.5d -2.1± 1.7d < 0.001
BMI at study baseline, kg/m2 32.4± 6.3 33.2± 5.6 31.1± 5.0 0.41
BMI at end-of-trial, kg/m2 32.5± 6.5 32.7± 5.8 30.3± 5.0 0.27
BMI change, kg/m2 0.1± 0.5 -0.5± 0.5d -0.8± 0.6d < 0.001
MET-h/d 28.5± 2.3 28.7± 2.1 28.9± 2.0 0.85
SBP,mmHg 118.7± 4.5 119.1± 4.2 119.2± 4.1 0.90
DBP,mmHg 79.5± 3.1 79.1± 2.8 79.4± 2.9 0.90
aValues are expressed as means± SD or No. (%).
bObtained from ANOVA test.
cObtained from Pearson Chi-square test.
dSignificant difference with the placebo group.
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; METs, metabolic equivalents; SBP, systolic blood pressure.
Table 2. Dietary Intakes of Participants Throughout the Studya
Value Placebo Group, n = 24 Low-Dose Cuminum cyminum L. Plus Lime
Group, n = 24
High-Dose Cuminum cyminum L. Plus Lime
Group, n = 24
P Valueb
Energy, kcal/d 2497± 161 2518± 169 2529± 168 0.80
Carbohydrates, g/d 340.4± 42.1 344.1± 43.4 343.9± 33.8 0.93
Protein, g/d 89.5± 10.3 87.9± 14.1 92.5± 13.3 0.44
Fat, g/d 91.0± 12.0 91.8± 13.1 90.6± 12.4 0.94
SFA, g/d 26.3± 5.5 26.2± 5.6 27.4± 5.2 0.72
PUFA, g/d 30.2± 8.3 27.8± 7.6 28.1± 6.5 0.46
MUFA, g/d 24.4± 4.4 25.2± 6.6 26.5± 6.7 0.45
Cholesterol,mg/d 201.2± 101.2 211.6± 123.1 226.3± 127.3 0.76
TDF, g/d 20.2± 4.2 18.8± 5.4 20.2± 4.6 0.50
aValues are expressed as means± SD.
bObtained from ANOVA test.
Abbreviations: MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; TDF, total dietary fiber.
effects on weight, BMI, FPG, QUICKI, triglycerides, total-
cholesterol and LDL-cholesterol levels. No significant ef-
fect of C. cyminum L. plus lime intake was observed on in-
sulin, HOMA-IR, HOMA-B, HDL-cholesterol and biomarkers
of oxidative stress. To the authors’ best knowledge, the cur-
rent study was the first that evaluated the beneficial effects
of C. cyminum L. plus lime administration on weight and
metabolic status in subjects with overweight.
Subjects with overweight are susceptible to several
diseases including coronary heart disease, T2DM, certain
types of cancer and osteoarthritis (18). The current study
revealed that taking high-dose C. cyminum L. plus lime for
eight weeks among subjects with overweight led to signif-
icant decrease in weight and BMI compared with low-dose
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Table 3. The Effects of Cumin Plus Lime Intake on Markers of Insulin Resistance, Lipid Profiles and Biomarkers of Oxidative Stress (n = 24)a
Value Placebo Group Low-Dose C. cyminum L. Plus Lime Group High-Dose C. cyminum L. Plus Lime Group P Valueb
Wk0 Wk 8 Change Wk0 Wk 8 Change Wk0 Wk 8 Change Time Group Time x
Group
FPG,mg/dL 87.0 (22.2) 90.0 (25.2) 0 (12.3) 97.5 (12.2) 87.0 (17.5) -9.0 (16.0) 101.5 (12.0) 82.5 (20.2) -22.0 (9.0) - - < 0.001c
Insulin,
µIU/mL
8.0± 3.2 7.6± 3.0 -0.4± 2.0 8.4± 2.7 7.8± 3.1 -0.6± 3.2 8.7± 4.2 7.4± 3.3 -1.3± 3.5 0.03 0.92 0.57
HOMA-IR 1.8± 0.9 1.8± 0.7 -0.04± 0.6 2.1± 0.7 1.9± 0.9 -0.2± 1.0 2.4± 1.1 1.8± 1.2 -0.6± 1.0 0.004 0.57 0.06
HOMA-B 29.0± 15.1 26.6± 15.5 -2.4± 9.5 27.1± 12.1 27.7± 15.9 0.6± 13.8 25.9± 17.9 27.1± 15.6 1.2± 12.9 0.87 0.94 0.53
QUICKI 0.35± 0.02 0.34± 0.02 -0.01± 0.01 0.34± 0.01 0.35± 0.02 0.01± 0.02 0.34± 0.02 0.36± 0.03 0.02±
0.02d
< 0.001 0.70 0.01
TG,mg/dL 124.5± 51.4 135.1± 56.2 10.6± 25.1 116.7± 57.1 130.5± 54.9 13.9± 36.8 138.7± 81.3 123.6± 52.8 -14.1± 56.2e 0.52 0.88 0.03
TC,mg/dL 187.3± 30.1 186.3± 37.4 -1.0± 24.8 174.8± 37.0 183.4± 43.2 8.6± 28.5 176.2± 34.7 157.8± 34.0 -18.4± 28.6e 0.26 0.12 0.004
LDL-C,
mg/dL
108.0± 23.3 105.1± 32.3 -2.9± 20.4 96.5± 30.1 103.0± 35.5 6.5± 23.2 93.7± 25.4 81.9± 27.6 -11.8± 20.7e 0.29 0.06 0.01
HDL-C,
mg/dL
54.4± 14.2 54.1± 15.2 -0.3± 7.7 55.0± 9.5 54.3± 10.8 -0.7± 5.4 54.8± 5.6 51.2± 6.4 -3.6± 6.3 0.05 0.84 0.16
TAC,mM/ 748.6±
155.4
777.6± 156.5 29.0± 107.0 789.9±
186.3
844.9± 118.1 54.9± 162.0 741.3± 89.4 783.1± 74.3 41.7± 53.3 0.003 0.21 0.74
GSH,(µM/L) 593.9±
229.0
570.1± 194.8 -23.8± 204.7 579.6± 112.2 555.9± 90.1 -23.8± 98.0 501.6± 113.5 489.0±
132.9
-12.6± 148.1 0.28 0.05 0.96
a Values are expressed as means± SD or No. (%) for normally distributed variables and median (IQR) for non-normally distributed variables.
b Obtained from repeated measures ANOVA test.
c Obtained from Kruskal-Wallis test.
d Significant difference with the placebo group.
e Significant difference with low-dose Cuminum cyminum L. plus lime group.
Abbreviations: FPG, fasting plasma glucose; HOMA-IR, homeostasis model of assessment-insulin resistance; HOMA-B, homeostatic model assessment-Beta cell function; QUICKI, quantitative insulin sensitivity check index; LDL-C, low
density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TC, total cholesterol; TG, triglycerides; TAC, total antioxidant capacity; GSH, total glutathione.
Table 4. Adjusted Changes in Metabolic Variables of Patients With Overweighta
Value Placebo, n = 24 Low-Dose Cuminum cyminum L. Plus Lime, n = 24 High-Dose Cuminum cyminum L. Plus Lime, n = 24 P Valueb
FPG,mg/dL 1.8± 4.3 -6.6± 4.1 -19.2± 4.1 0.004
Insulin,µIU/mL -0.4± 0.5 -0.7± 0.5 -1.0± 0.5 0.75
HOMA-IR -0.2± 0.2 -0.2± 0.2 -0.5± 0.2 0.47
HOMA-B -0.7± 2.4 -0.6± 2.3 0.6± 2.3 0.89
QUICKI 0.003± 0.005 0.009± 0.005 0.02± 0.005 0.06
TG,mg/dL 9.3± 7.4 9.3± 7.3 -9.2± 7.3 0.13
TC,mg/dL 0.4± 5.7 8.1± 5.7 -19.3± 5.6 0.003
LDL-C,mg/dL -2.1± 4.6 6.9± 4.5 -12.8± 4.5 0.01
HDL-C,mg/dL -0.4± 1.4 -0.8± 1.4 -3.4± 1.3 0.22
TAC,mM/L 21.2± 19.7 69.7± 19.7 34.7± 19.3 0.21
GSH,µM/L 3.9± 26.9 -20.9± 26.8 -43.0± 26.8 0.48
aAll values are expressed as means± SE. Adjusted for baseline values, age and baseline BMI.
bObtained from ANCOVA.
Abbreviations: FPG, fasting plasma glucose; HOMA-IR, homeostasis model of assessment-insulin resistance; HOMA-B, homeostatic model assessment-Beta cell function;
QUICKI, quantitative insulin sensitivity check index; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TC, total cholesterol; TG,
triglycerides; TAC, total antioxidant capacity; GSH, total glutathione.
C. cyminum L. plus lime and placebo. Supporting the cur-
rent study, authors’ previous study showed that taking 300
mgC. cyminum L. among subjects with overweight for eight
weeks resulted in significant decrease in weight and BMI
(9). In addition, a reduction in body weight and food con-
sumption was observed following the intake of lime essen-
tial oil in mice after 45 days (10). The same findings were re-
ported among males with obesity following the consump-
tion of 1.5 g black cumin daily for three months (19) and
in rats after intake of 5 mg/kg per day thymoquinone for
five days (20). The exact mechanism by whichC. cyminum L.
and lime intake might affect weight and BMI are unknown.
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It is possible that phytoestrogens of C. cyminum L. inhibit
serotonin re-uptake and thereby increase the levels of sero-
tonin in synaptic clefts (12), which in turn would result in
enhanced satiety. In addition, limonene may reduce body
weight through increased lipolysis by a histaminergic re-
sponse and reduced appetite (13).
The current study indicated that high-dose C. cyminum
L. plus lime administration for eight weeks among sub-
jects with overweight was associated with a significant re-
duction in FPG and a significant rise in QUICKI compared
with low-dose C. cyminum L. and lime and placebo, but
did not influence serum insulin, HOMA-IR and HOMA-B. In
agreement with the current study, a significant decrease
of serum glucose levels was observed in obese rats treated
with extracts of herbal mixture formulation for four weeks
(12). Moreover, d-limonene consumption lowered FPG lev-
els in obese mice (11). Improved insulin sensitivity was also
observed following the administration of various com-
binations of essential oils such as fenugreek, cinnamon,
cumin and oregano in Zucker fatty rats (21). In addition,
treatment with antioxidant supplementation, including d-
limonene and vitamin E, improved insulin sensitivity in
obese rabbits after two months (22). Cumin intake may re-
sult in improved insulin sensitivity via preserving pancre-
atic beta-cell integrity (23). In addition, anti-inflammatory
properties of d-limonene may lead to improved insulin
function (24).
The current study showed that taking high-dose C.
cyminum L. plus lime for eight weeks among subjects
with overweight resulted in significant decrease in triglyc-
erides, total-cholesterol and LDL-cholesterol concentra-
tions compared with low-dose C. cyminum L. plus lime
and placebo, but did not affect HDL-cholesterol and ox-
idative stress biomarkers. In line with the current study,
significant decrease in serum total-cholesterol and LDL-
cholesterol levels were observed in the birds fed with black
seed (4 g/kg) for 28 days (25). A 20-week administra-
tion of Nigella sativa also led to a significant decrease in
LDL-cholesterol concentrations in rats. Furthermore, d-
limonene intake in obese mice resulted in a significant de-
crease in triglycerides and LDL-cholesterol levels (11). Ad-
ministration of limonene in diabetic rats for 45 days led
to a significant increase in the activities of antioxidant en-
zymes (26). However, such beneficial effects observed in
few studies. For instance, taking cumin extract three times
a day in patients with hypercholesterolemia for six weeks
did not influence lipid profiles (27). Similar findings were
observed following the treatment of C. cyminum methanol
extract at dose levels of 100 and 200 mg/day in male albino
rats after 60 days (28). Previous studies showed that phy-
tosterols of C. cyminum have the ability to reduce the in-
testinal absorption of diet biliary cholesterol (12, 29). Lime
intake may result in improved lipid profiles through ac-
tivating peroxisome proliferator-activated receptor-α sig-
naling, and inhibited liver X receptor-β signaling (11). Ab-
sence of significant effect on HDL-cholesterol and oxida-
tive stress biomarkers following the administration of C.
cyminum L. plus lime in the current study might be me-
diated by the different study designs, discrepancy in sub-
jects, different doses of C. cyminum and duration of the
study.
Some of the main strengths of the current study were
the assessment of insulin resistance markers, lipid pro-
files, oxidative biomarkers and the randomized design.
Some limitations should be taken in account in the inter-
pretation of the results. Beneficial effects of C. cyminum
L. plus lime intake on leptin, thyroid hormones and in-
flammatory cytokines were not evaluated. Furthermore,
the sample size was small and duration of the intervention
was short in the current study. Further studies with bigger
sample sizes, and longer duration of the intervention are
needed to confirm the findings.
Taken together, the current study indicated that taking
high-dose C. cyminum L. plus lime for eight-week among
subjects with overweight had beneficial effects on weight,
BMI, FPG, QUICKI, triglycerides, total-cholesterol and LDL-
cholesterol levels; however, it did not affect insulin, HOMA-
IR, HOMA-B, HDL-cholesterol and oxidative stress biomark-
ers.
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